New Enterprise Associates

New Enterprise Associates (NEA) is a prominent venture capital firm established in 1977, headquartered in Menlo Park, California, with additional offices in the U.S., India, and China. NEA specializes in investing in technology and healthcare sectors, with a focus on enterprise, consumer, fintech, life sciences, and digital health companies. The firm engages with entrepreneurs at various stages of business development, providing support from initial funding to public offerings. NEA invests globally, with a significant presence in Asia, including China and India, as well as the United States. The firm typically invests between $0.05 million and $20 million per deal.

Michael Albert

Associate

Kate Barrett

Partner, Communications

Forest Baskett

General Partner

Ron Bernal

Venture Partner

Ann Bordetsky

Partner

Zak Burns

Associate

James Buxton MD

Principal

Carmen Chang

Partner, Chair and Head of Asia

Tak Cheung

Partner

Philip Chopin

Managing Director, NEA UK

Pamela Clark

General Partner

Vanessa Deng

Associate

Chris Doppman

Principal, LP Relations

Tony Florence

General Partner

Scott Gottlieb

Partner

Jay Graf

Venture Partner

Lily Huang

Principal, Healthcare VC

Aaron Jacobson

Partner

Arjun Jain

Senior Associate

James Kaplan

Associate

Patrick Kerins

General Partner

Nick Kline

Principal, LP Relations

Vanessa Larco

Partner

Danielle Lay

Principal

Tiffany Le

Principal

Michael Li

Principal

Tiffany Luck

Partner

Mohamad Makhzoumi

General Partner

Matthew McAviney

Partner

Amit Mukherjee

Partner

Bibhash Mukhopadhyay

Principal

Kemi Odusan

Senior Associate

Jess Ou

Senior Associate

Greg Papadopoulos

Venture Partner

Luke Pappas

Principal

Eileen Qian

Associate

Scott Sandell

Managing General Partner

Tim Schaller

CFO

Alex Sharata

Associate

George Stamas

Venture Partner

Brad Thawley

Partner, Limited Partner Relations

Lila Tretikov

Partner

Paul Walker

General Partner

Blake Wu

Partner

Lulu Xu

Principal

Rick Yang

Partner, Head of Technology

Emily Zhen

Associate

Arno Penzias Ph.D

Venture Partner

J.C. Lopez

Principal

2244 past transactions

Chaos

Series C in 2025
Chaos Industries is a technology company specializing in next-generation solutions for defense and critical industries. The company is dedicated to enhancing sensing, detection, and communication capabilities through the use of Coherent Distributed Networks (CDN). Its focus on detection and radar services supports the development of advanced defense products, allowing clients to access high-quality services tailored to their needs.

Veza

Series D in 2025
Veza is the data security platform that helps users use and share their data safely. It makes it easy to understand, manage, and control who can and should take what action on what data. It organizes authorization metadata across identity providers, data systems, cloud service providers, and applications, all to address the toughest data security challenges of the modern era. The company is funded by top-tier investors including Accel, Bain Capital, Ballistic Ventures, Blackstone, GV, Norwest Venture Partners, and True Ventures.

Glacier

Series A in 2025
Glacier, founded in 2019 and based in San Francisco, California, has developed the first affordable, high-performing, and space-efficient AI-enabled robot designed specifically for recycling. The company aims to transform the recycling industry by utilizing artificial intelligence-powered sensors and robotics to automate the sorting of recyclable materials. This innovative approach allows recycling facilities to enhance their operational efficiency, improve sorting accuracy, and ultimately increase profitability. By integrating advanced technology into the recycling process, Glacier is positioned to significantly impact how recycling facilities manage and process materials.

Plaid

Venture Round in 2025
Plaid Inc. is a technology company that facilitates the connection between consumers' bank accounts and applications, aiming to democratize financial services through advanced technological solutions. Founded in 2012 and headquartered in San Francisco, it provides a comprehensive suite of APIs that enable developers to create financial products connecting users with traditional financial institutions. Plaid's offerings include tools for accessing transaction history and balance data, authenticating bank accounts for payments, verifying identities, and confirming real-time account balances and income. These products support various applications in personal finances, consumer payments, lending, banking, and business finance. With a focus on enhancing both consumer experiences and developer capabilities, Plaid serves a diverse range of clients, including Fortune 50 companies, positioning itself as a vital infrastructure provider in the digital financial landscape.

Aetherflux

Series A in 2025
Aetherflux is an aerospace company that designs and operates a constellation of small satellites to harvest sunlight in space, convert it into electricity, and wirelessly transmit power to ground stations. This innovative approach aims to provide reliable, renewable energy to households, businesses, and military operations worldwide, reducing environmental impact.

Vori Health

Series B in 2025
Vori Health is a healthcare provider focused on treating musculoskeletal conditions through an integrated care delivery model. Founded in 2020 and headquartered in New York, the organization offers a comprehensive range of services, including physical therapy, medical assessments, lab and imaging orders, health coaching, and nutritional guidance. Vori Health employs a virtual-first approach to connect patients with a collaborative care team, consisting of board-certified physical medicine physicians, health coach navigators, and physical therapists. This model aims to facilitate effective management of back, neck, and joint issues, guiding patients toward optimal wellness and recovery. By combining evidence-based practices with personalized support, Vori Health strives to improve patient outcomes in musculoskeletal care.

Ceramic

Seed Round in 2025
Ceramic operates as an Artificial Intelligence company.

Ceramic

Seed Round in 2025
Ceramic operates as an Artificial Intelligence company.

Metronome

Series C in 2025
Metronome is a billing infrastructure company that specializes in supporting software companies with usage-based business models. The company's platform provides metering and data mediation software, ensuring a robust data infrastructure and real-time architecture for effective billing. Metronome emphasizes rapid deployment and user-friendliness, allowing business and product teams to manage revenue and pricing with minimal engineering effort. After integrating the platform, teams can swiftly introduce new products and pricing structures, streamline revenue workflows, and offer customers immediate visibility into their spending. This flexibility enables companies to efficiently launch, iterate, and scale their operations.

Cambium Carbon

Series A in 2025
Cambium Carbon is an early-stage social enterprise focused on addressing climate change through innovative reforestation and urban wood reuse initiatives. The company collaborates with cities and various public and private partners to salvage fallen city trees that would otherwise end up in landfills. By transforming this wood waste into valuable resources, Cambium Carbon establishes reforestation hubs that create a circular economy for urban forests. These hubs not only generate revenue to support tree planting and maintenance projects but also foster sustainable job creation and contribute to the development of resilient urban environments. Through its efforts, Cambium Carbon aims to implement systems-level natural climate solutions that benefit both the environment and local communities.

Abcuro

Series C in 2025
Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Based in Newton, Massachusetts, Abcuro creates therapeutic antibodies targeting novel mechanisms related to these diseases. The company utilizes advanced bioinformatics to analyze transcription data from human diseases, which aids in the identification of new therapeutic targets. Through ex-vivo validation in diseased tissues, Abcuro seeks to uncover innovative methods to modulate key components of the immune system. Established in 2015, Abcuro aims to enhance treatment strategies in the healthcare industry by offering effective solutions for complex immunological conditions.

Music AI

Series A in 2025
Music AI is a software development company that provides artificial intelligence solutions for music and audio technology.

Instabase

Series D in 2025
Instabase, Inc. is a technology company based in San Francisco, California, founded in 2015. It specializes in developing a platform that automates document processing workflows and analyzes unstructured data. The platform integrates various capabilities, including optical character recognition, data classification and extraction, and natural language processing, allowing organizations across sectors such as insurance, finance, and healthcare to streamline operations and improve decision-making. Additionally, Instabase provides a developer kit that enables the creation of customized business applications, helping institutions embed artificial intelligence into their systems and processes. Through its innovative solutions, Instabase aims to address significant business challenges and facilitate transformational outcomes for its clients.

Synthesia

Series D in 2025
Synthesia Ltd. is a London-based company that specializes in an artificial intelligence-driven video production platform. Founded in 2017, the company offers a service that transforms text into professional-quality videos featuring customizable avatars and voiceovers in over 140 languages. Its innovative video synthesis technology allows users to create high-end videos for various applications, including personalized advertising, corporate communications, e-learning, and marketing. By synchronizing lip movements with new dialogue tracks, the platform facilitates the translation of video content into different languages, thereby enhancing distribution channels. Users can quickly create, edit, and share studio-quality videos directly in their browser, utilizing fully cloneable AI video templates to streamline production and meet diverse content needs.

Tune Therapeutics

Series B in 2025
Tune Therapeutics is focused on developing innovative cell and gene therapies that utilize epigenetic programming to address serious diseases. By harnessing the epigenome, the company aims to create new pathways for treatment without making changes to the DNA sequence itself. This approach allows for the potential development of therapies for complex and widespread medical conditions, positioning Tune Therapeutics at the forefront of advancements in the field of epigenetics.

Ouro Medicines

Series A in 2025
Ouroboros Medicines is a biotechnology company that specializes in immunology and focuses on treating long-term immune-mediated illnesses. The company addresses chronic immune-mediated conditions directly by integrating scientific knowledge, a proven history of progressing cell-depleting treatments through clinical trials, and a strong pipeline.

Fire1

Venture Round in 2025
Fire1, based in Dublin, Ireland, is dedicated to developing innovative therapeutic devices aimed at enhancing the lives of heart failure patients. The company has created a remote monitoring system that allows healthcare providers to access real-time patient data and insights. This technology facilitates the early detection of complications associated with heart failure, enabling proactive interventions that can lead to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to address critical challenges in heart failure management and contribute to better healthcare solutions.

Orbis Medicines

Series A in 2025
Orbis Medicines is a company focused on drug discovery, utilizing a unique macrocyclic chemistry and computational platform to develop new therapeutics. By employing high-throughput techniques, Orbis aims to accelerate the drug discovery process, particularly for challenging targets that address significant unmet medical needs. Their innovative approach is designed to enhance the efficiency and effectiveness of developing treatments, ultimately improving patient outcomes.

NeueHealth

Acquisition in 2024
NeueHealth Inc is a healthcare company dedicated to providing high-quality, coordinated care to all health consumers, particularly those in aging and underserved populations. The company focuses on making healthcare accessible and affordable through strategic partnerships with providers and payors, aligning their interests to enhance the overall healthcare experience. By leveraging technology and data analytics, NeueHealth offers a suite of services that empower independent providers and medical groups to succeed in performance-based arrangements. This approach not only optimizes clinical outcomes but also aims to drive down costs and reduce systemic waste, ultimately delivering a more personalized and efficient healthcare experience for its members across various insurance markets, including the ACA Marketplace, Medicare, and Medicaid.

Courtyard.io

Venture Round in 2024
Courtyard is a platform that facilitates the liquidity of collectible assets by tokenizing them into non-fungible tokens (NFTs) backed by physical items. This service allows for the secure and instant transfer of ownership of physical collectibles globally, without the need for the actual items to be physically moved. The company provides secure storage for these collectibles in vaults, creates three-dimensional representations of the assets, and mints them as NFTs on the blockchain. By streamlining the authentication process at each transaction, Courtyard enhances the collectibles market, enabling collectors to showcase their collections in the metaverse and promoting a new, frictionless method of trading and storing physical goods.

Backflip AI

Series A in 2024
Backflip's 3D generative AI for the real world allows engineers and designers to work at their own pace and creative constraints. Anyone may use its AI-powered 3D design tools to realize their ideas and produce incredibly realistic models that can be printed out or used as video game assets, 3D renders, and other digital media.

Senti Bio

Post in 2024
Senti Biosciences is a clinical-stage biotechnology company specializing in synthetic biology and gene circuit engineering for therapeutic purposes. The company employs its Gene Circuits platform to develop innovative therapies that enhance precision in targeting cancer cells while avoiding damage to healthy cells. Senti Bio's approach involves the use of allogeneic chimeric antigen receptor natural killer (CAR-NK) cells that incorporate its gene circuit technologies, aimed at addressing various oncology indications. Among its product candidates are SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively eliminate cancer cells without harming healthy bone marrow, and SENTI-301A, which targets hepatocellular carcinoma. Senti Biosciences aims to provide effective treatment options for difficult-to-treat diseases through advanced cell and gene therapies.

Avenzo

Series A in 2024
Avenzo Therapeutics is a clinical-stage company focused on developing innovative oncology therapies aimed at treating cancer. The company’s platform is dedicated to creating novel treatments specifically for underserved cancers, including rare and genomically defined types. By advancing a pipeline of targeted drug candidates, Avenzo Therapeutics seeks to enhance treatment options for both researchers and patients, addressing significant gaps in current cancer care.

Fastino

Pre Seed Round in 2024
Fastino provides enterprise AI developers with high-performance, task-optimized language models built to scale.

Sana

Series C in 2024
Sana is an AI company building AI for enterprise knowledge.

Pathos

Series C in 2024
Pathos is a company that focuses on enhancing the drug discovery process through its AI-enabled platform. This self-learning technology leverages big data and artificial intelligence to streamline the identification and validation of drug targets, ultimately establishing their clinical efficacy. By facilitating the exploration of novel concepts, Pathos aims to support drug developers in advancing innovative therapies. The platform is designed to manage the entire end-to-end process of designing and developing new therapeutics, thereby significantly reducing the time required for medication development.

Outrider

Series D in 2024
Outrider, Inc. is a software company that specializes in automating logistics hubs through the use of electric, self-driving trucks. Established in 2017 and based in Golden, Colorado, Outrider provides a software-as-a-service (SaaS) solution designed for customer-owned freight and transportation fleets. The company offers a comprehensive system comprised of web-based management software, autonomous driving controls for electric yard trucks, and necessary site infrastructure. Its technology automates various yard operations, including the movement of trailers and the engagement and disengagement of trailer connections, thereby eliminating hazardous and repetitive manual tasks. By focusing on the development of zero-emission systems, Outrider aims to enhance safety and efficiency for large enterprises reliant on logistics.

Genmo

Series A in 2024
Genmo is an artificial intelligence creative content generation platform that specializes in developing creative products.

Inventiva Pharma

Post in 2024
Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

Firestorm

Series A in 2024
Firestorm is focused on developing modular open-source architecture tailored to meet the needs of the Department of Defense, emphasizing affordability and mass production. The company specializes in the manufacturing of loitering munitions and mission-adaptable systems designed to enhance aerial weaponry. Its products offer significant modularity and precision in payload delivery, equipping paratroopers with advanced aircraft suitable for modern combat scenarios. By prioritizing low-cost solutions, Firestorm aims to contribute to the evolving demands of the hyper-enabled battlefield.

Wispr Flow

Venture Round in 2024
Wispr Flow is a developer of a personal computing platform aimed at an artificial intelligence-first future, emphasizing neural interfaces. The company focuses on a human-centered approach that integrates advancements in neurotechnology, machine learning, and hardware systems. By doing so, Wispr Flow seeks to make cutting-edge technology accessible to a wider audience, allowing users to engage with technology in a more intuitive and natural manner.

858 Therapeutics

Series B in 2024
858 Therapeutics is a biotechnology company dedicated to the discovery of small molecule therapeutics aimed at treating cancers and other diseases, particularly those resistant to existing therapies. The company employs innovative strategies in areas such as synthetic lethality, innate immunity, and RNA modulation to develop its therapeutic candidates. Its lead program focuses on a PARG inhibitor, which is currently in early clinical development. By leveraging its platform to investigate the role of RNA modifying proteins in disease biology, 858 Therapeutics is generating a pipeline of targeted small molecules that address critical unmet medical needs in oncology and immunology.

DeltaStream

Series A in 2024
DeltaStream operates a self-service stream processing platform designed to assist businesses in processing and analyzing streaming data in real time. The platform leverages Apache Flink to provide serverless stream processing, enabling users to build materialized views and conduct real-time analytics without the need for infrastructure management. Key features include data governance, unified views, third-party sharing, private software-as-a-service (SaaS), and query-level scaling. By addressing various streaming analytics and database use cases, DeltaStream offers limitless scalability, allowing organizations to effectively harness the power of their streaming data.

World Labs

Venture Round in 2024
World Labs is a developer of an artificial intelligence platform that enables humanlike processing of visual data. The company focuses on spatial intelligence, creating advanced AI systems that function in three-dimensional (3D) environments, both virtual and real. Their primary service involves building Large World Models (LWMs), which empower AI to perceive, generate, and interact with the world in 3D space. By leveraging synthetic data to train its models, World Labs provides companies with access to reliable computer vision technologies capable of accurately identifying objects. This innovative approach positions the company at the forefront of advancements in augmented and virtual reality.

Second Front

Series C in 2024
Second Front Systems, Inc. is a software development company based in Arlington, Virginia, that focuses on enhancing government access to venture capital-backed technologies for national security missions. Established in 2014, the company offers Atlas Fulcrum, a platform that helps users identify, assess, and utilize innovative commercial technologies. Additionally, Second Front provides program management and system integration services to facilitate the delivery of technology to military personnel. The High Technology Council, an enterprise consortium established by the company, brings together key industry players to leverage commercially developed technologies for government-funded national security efforts. Second Front also specializes in configuring, securing, and deploying compliant software applications for global government customers, ensuring that users have access to a fully managed production environment tailored for national security applications.

Agree.com

Pre Seed Round in 2024
Agree.com is the best solution for creating and managing contracts, streamlining negotiations, enhancing compliance, optimizing workflows, and converting more customers — all within one intuitive platform. View edits, track signatures, and get alerted on all upcoming key milestones. Include free, one-click e-signatures with identity verification on every agreement. Increase deal velocity and drive revenue impact with integrated payments.

Sakana AI

Series A in 2024
Sakana AI is an research company focused on creating innovative foundation models inspired by nature. The organization emphasizes evolution and collective intelligence in its AI development processes.

Ceramic

Seed Round in 2024
Ceramic operates as an Artificial Intelligence company.

PayZen

Series B in 2024
PayZen is a healthcare fintech startup founded in 2019 in San Francisco by Ariel Rosenthal, Itzik Cohen, and Tobias Mezger. The company addresses the challenge of patient payment responsibilities by providing a platform that allows patients to pay their out-of-pocket medical bills over time, enhancing convenience and transparency. PayZen's technology utilizes artificial intelligence to create tailored payment plans that cater to individual financial situations, thereby improving affordability for patients. This approach not only facilitates timely payments but also helps medical providers optimize cash flow and minimize the costs associated with collecting outstanding invoices. By focusing on patient financing solutions, PayZen enables healthcare providers to concentrate on delivering medical care rather than managing financial transactions.

Moximed

Series D in 2024
Moximed, Inc. is a medical technology company based in Hayward, California, focused on developing innovative solutions for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain for individuals suffering from medial compartment knee osteoarthritis. This system operates similarly to a shock absorber, providing dynamic load reduction to minimize joint pain and enhance mobility. Moximed also features the MISHA Knee System, which offers an outpatient treatment option for patients who have not found relief through other therapies and are not suitable candidates for knee replacement surgery. By addressing the specific needs of osteoarthritis patients, Moximed aims to improve their quality of life while potentially delaying the need for more invasive surgical interventions. Founded in 2006, the company serves patients and medical professionals worldwide.

MBX Biosciences

Series C in 2024
MBX Biosciences, Inc. is a biotechnology company based in Carmel, Indiana, specializing in the development of therapeutics for rare endocrine disorders. Established in 2018, the company focuses on creating peptides aimed at treating genetic diseases that affect glandular hormones, which play a crucial role in the body’s chemical messaging system. By targeting conditions with inadequate treatment options, MBX Biosciences is dedicated to discovering, developing, and commercializing innovative endocrine therapeutics.

Augment Markets

Seed Round in 2024
Augment is a developer of a platform designed for confidential transactions and communications, specifically tailored for the private technology share market. The platform facilitates connections between buyers and sellers by providing an order book within a company's marketplace. Users can identify potential transaction partners, engage in secure communication, and finalize deals, streamlining the process for brokers, investors, and shareholders. This innovative approach allows participants in private market trades to efficiently manage their transactions while maintaining anonymity and confidentiality.

Global Predictions

Seed Round in 2024
Global Predictions is a financial technology company founded by a team with extensive experience at Bridgewater, leveraging artificial intelligence to deliver investment insights and financial advice. The company has developed a proprietary Economic Insights Engine that powers its fintech solutions, making them accessible to millions through their API and tailored insights. Their flagship product, PortfolioPilot.com, serves as a personal AI financial advisor for individuals, managing over $30 billion in assets. The platform is designed to offer personalized recommendations and guidance for investment portfolio management, helping users navigate economic shifts effectively.

Clio

Series F in 2024
Clio is a Canadian company specializing in cloud-based practice management software for law firms. Its platform streamlines client management, billing, and communication, enabling lawyers to efficiently handle day-to-day tasks. Clio Ventures, an early-stage venture capital fund managed by Clio, invests in promising legal tech and SaaS startups, fostering innovation in the legal industry.

Magenta Medical

Venture Round in 2024
Magenta Medical Ltd. is a privately held company based in Kadima, Israel, founded in 2012. The company specializes in developing innovative medical devices aimed at treating acute decompensated heart failure. Its flagship product is a temporary venous catheter-based therapy that includes a self-expanding heart pump. This device targets critical issues related to acute heart failure, particularly renal venous congestion, which adversely affects both cardiac and renal function. By enabling physicians to more effectively manage fluid and salt removal in patients, Magenta Medical's technology enhances patient safety and supports kidney function, offering a promising solution for better management of heart failure.

Cardurion Pharmaceuticals

Series B in 2024
Cardurion Pharmaceuticals, LLC is a biotechnology company based in Boston, Massachusetts, established in 2017. The company specializes in developing innovative therapeutics aimed at treating heart failure and other cardiovascular diseases. Cardurion is advancing clinical programs that focus on inhibiting PDE9 and CaMKII, utilizing its knowledge of cardiovascular signaling pathways to meet significant patient needs in this area.

Amber Therapeutics

Series A in 2024
Amber Therapeutics is a biotechnology company that specializes in developing advanced bioelectrical therapies aimed at treating functional disorders of the peripheral nervous system. The company creates a bioelectronic platform that delivers closed-loop bioelectrical treatments, which can sense and adapt to the patient's needs while also providing stimulation. By focusing on conditions such as mixed urinary incontinence, Amber Therapeutics seeks to enhance clinical efficacy and patient outcomes through innovative approaches that emphasize the peripheral nervous system rather than the central nervous system. Its technology has the potential to significantly improve treatment methods and overall patient care in targeted disease areas.

Twelve Labs

Series A in 2024
Twelve Labs specializes in a multimodal artificial intelligence platform designed to enhance video understanding across various applications. The platform enables businesses and developers to analyze video content by integrating visual and auditory data, facilitating the creation of intelligent video applications. It offers APIs for functions such as searching, generating, and classifying video content, allowing users to deploy solutions on any cloud, customize models, and fine-tune with their own data. Twelve Labs serves diverse industries, including technology, media, entertainment, and security, empowering clients to harness complex video information for a range of downstream tasks.

Faircado

Pre Seed Round in 2024
Faircado operates a sustainable shopping platform designed to enhance the circularity of produced goods by promoting second-hand purchases. The platform employs a smart algorithm that aggregates offers from major pre-owned marketplaces, allowing users to compare prices and sustainability scores of second-hand items across various categories, including electronics and books. This centralized approach enables consumers to make informed decisions while shopping, ultimately saving time, money, and resources. Faircado's commitment to reducing waste aligns with its mission to foster a more sustainable shopping experience.

In-House Health

Seed Round in 2024
In-House Health is an AI-powered technical platform for modern nursing teams.

Zenas BioPharma

Series C in 2024
Zenas BioPharma is a clinical-stage biopharmaceutical company based in Florida, dedicated to developing immune-based therapies for patients. The company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody that targets both CD19 and FcγRIIb, which are found on B cells. This innovative approach aims to inhibit the activity of B cells involved in various autoimmune diseases while preserving their overall population, thus offering a potential therapeutic advantage over traditional treatments that deplete these cells.

SafeBase

Series B in 2024
SafeBase, Inc. is a San Francisco-based company founded in 2020 that specializes in cloud-based security software aimed at helping organizations establish and enhance their security programs. The company’s offerings include a smart trust center platform that facilitates the sharing of security posture and automates access to sensitive documents. SafeBase provides solutions such as SafeBase Inspected, which features a website badge linking to a custom security status page, as well as custom security checklists and continuous monitoring of security systems. Additionally, the software assists organizations in configuring security policies, thereby enabling them to implement robust security practices effectively.

Beehiiv

Series B in 2024
Beehiiv is an email newsletter platform that empowers creators to produce, monetize, and expand their newsletters. The platform enhances audience engagement and growth through advanced customization and superior analytics, allowing users to effectively scale their web and email content. Beehiiv's direct engagement model reduces reliance on cookie-based data, providing a more reliable method for publishers and advertisers to connect with their audiences. Notably, the company does not take a share of subscription revenue, offering a more lucrative financial model for creators looking to maximize their earnings.

ARRIS

Venture Round in 2024
ARRIS specializes in additive molding technology for creating advanced performance composites tailored for mass-market applications such as aerospace, automotive, and consumer products. The company’s innovative manufacturing process focuses on the precise alignment of continuous carbon fibers, allowing for the integration of electronic components and multifunctional materials into a single, topologically optimized part. This technology enables clients to leverage high-performance composites, enhancing the capabilities and efficiency of their products while meeting the demands of modern manufacturing.

Xaira Therapeutics

Venture Round in 2024
Xaira Therapeutics is an integrated biotechnology company focused on revolutionizing drug discovery and development through the application of artificial intelligence. Headquartered in the San Francisco Bay Area, Xaira combines expertise in machine learning, extensive biological and clinical data generation, and robust therapeutic product development. By harnessing advanced AI techniques, the company aims to enhance the understanding of biological processes and improve the effectiveness of therapies. Xaira's approach encompasses all stages of drug discovery, striving to transform how diseases are treated and enabling clients to deliver innovative therapeutic solutions.

Perplexity

Venture Round in 2024
Perplexity is an artificial intelligence-based search engine platform that combines large language models with traditional search engines. It leverages natural language processing and generative AI technologies to deliver conversational responses to user queries, aiming to enhance the search experience beyond standard results. The platform is designed to facilitate the development of safe and beneficial artificial general intelligence, offering an open-source environment accessible to the public. This allows clients to acquire skills and knowledge in software development, positioning Perplexity as a bridge between conventional search capabilities and advanced AI-driven assistance.

Korro Bio

Post in 2024
Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

AI Squared

Series A in 2024
AI Squared helps large organizations bring AI to where work happens. We do this by leveraging our SaaS or on-prem platform which combines data sources with advanced AL/ML functionality and embeds intelligent insights into critical business applications. Trusted by the largest financial institutions, the most complicated supply chain logistics companies, and the US Department of Defense, we enable seamless collaboration between data science teams and business users, driving faster, more informed decision-making.

Avenzo

Series A in 2024
Avenzo Therapeutics is a clinical-stage company focused on developing innovative oncology therapies aimed at treating cancer. The company’s platform is dedicated to creating novel treatments specifically for underserved cancers, including rare and genomically defined types. By advancing a pipeline of targeted drug candidates, Avenzo Therapeutics seeks to enhance treatment options for both researchers and patients, addressing significant gaps in current cancer care.

Foundry

Series A in 2024
Foundry is a public cloud supported by an orchestration platform designed to simplify the utilization of AI computing resources. Foundry addresses fundamental economic and technical obstacles encountered in AI and deep learning. Current challenges faced by businesses, such as the notable GPU scarcity and inefficient use of computing capabilities, hinder their effective utilization of resources. Foundry employs pioneering approaches to overcome these hurdles, offering scalable GPU instances with unparalleled price-performance ratios.

Wonder

Venture Round in 2024
Wonder is a technology company that specializes in gaming and food delivery services. It offers an all-in-one gaming platform for Android mobile devices, enabling users to play, stream, and share games across various devices. Additionally, Wonder operates a food delivery service using trucks that function as mobile restaurants. Customers order food through a mobile app, and the Wonder trucks drive to a location near the user's home to prepare and deliver fresh meals on-site.

Lily AI

Series B in 2024
Lily AI is a developer of an e-commerce product discovery platform that enhances the sales capabilities of brands and retailers. The platform integrates customer-centric product attributes into various components of the e-commerce ecosystem, including site search engines, recommendation systems, and SEO/SEM functionalities. By improving on-site search and personalized product discovery, Lily AI supports retailers in the fashion, home, and beauty sectors, leading to significant increases in traffic, conversion rates, revenue, and brand loyalty. Headquartered in Mountain View, California, the company is backed by venture capital.

Together AI

Series A in 2024
Together AI is a cloud-based platform designed for constructing open-source generative AI and infrastructure for developing AI models. The company contributes cutting-edge open-source research, models, and datasets to push the boundaries of AI forward. Through its decentralized cloud services, developers and researchers at organizations of various scales are empowered to train, refine, and deploy generative AI models.

Regulus Therapeutics

Post in 2024
Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company based in San Diego, California, specializing in the discovery and development of therapies that target microRNAs for various diseases. The company is advancing its lead product candidates, RG-012 and RGLS4326, which are in Phase II and Phase Ib clinical trials, respectively. RG-012 targets miR-21 for the treatment of Alport syndrome, a severe kidney disease, while RGLS4326 targets miR-17 for autosomal dominant polycystic kidney disease. In addition to these candidates, Regulus is developing a pipeline of preclinical drug products, including RGLS5579, aimed at inhibiting miR-10b, as well as programs targeting hepatitis B virus and non-alcoholic steatohepatitis. Founded in 2007, Regulus Therapeutics is at the forefront of leveraging the therapeutic potential of microRNA, a significant scientific breakthrough in recent years.

Propense.ai

Seed Round in 2024
Propense.ai is a Software as a Service (SaaS) company that helps businesses identify new revenue streams using artificial intelligence. Its B2B predictive sales intelligence platform analyzes historical and market data to uncover hidden revenue opportunities, enabling firms to optimize cross-selling and maximize sales. The platform provides real-time insights, precise forecasting, and strategic intelligence, allowing businesses to serve clients better, gain valuable insights, and ultimately increase revenue.

Glacier

Venture Round in 2024
Glacier, founded in 2019 and based in San Francisco, California, has developed the first affordable, high-performing, and space-efficient AI-enabled robot designed specifically for recycling. The company aims to transform the recycling industry by utilizing artificial intelligence-powered sensors and robotics to automate the sorting of recyclable materials. This innovative approach allows recycling facilities to enhance their operational efficiency, improve sorting accuracy, and ultimately increase profitability. By integrating advanced technology into the recycling process, Glacier is positioned to significantly impact how recycling facilities manage and process materials.

Inkitt

Series C in 2024
Inkitt GmbH operates an online community that connects writers and readers, facilitating the sharing and promotion of stories across various genres, including horror, romance, and sci-fi. Founded in 2013 and based in Berlin, the company publishes books using crowd wisdom and data-driven insights to predict future bestsellers. Its core platform, Inkitt, allows authors to share their works in progress and receive feedback from readers, who can access these manuscripts for free for a limited time. In addition to Inkitt, the company also operates Galatea, which sells optimized stories in a chapter-by-chapter format, and GalateaTV, which adapts successful e-books into short-form television series. Inkitt's proprietary ReadRank algorithm identifies high-potential stories, enhancing the overall user experience and driving its publishing success. The company aims to leverage AI for hyper-personalization, tailoring stories to individual reader preferences across multiple media formats.

Genmo

Venture Round in 2024
Genmo is an artificial intelligence creative content generation platform that specializes in developing creative products.

Metronome

Series B in 2024
Metronome is a billing infrastructure company that specializes in supporting software companies with usage-based business models. The company's platform provides metering and data mediation software, ensuring a robust data infrastructure and real-time architecture for effective billing. Metronome emphasizes rapid deployment and user-friendliness, allowing business and product teams to manage revenue and pricing with minimal engineering effort. After integrating the platform, teams can swiftly introduce new products and pricing structures, streamline revenue workflows, and offer customers immediate visibility into their spending. This flexibility enables companies to efficiently launch, iterate, and scale their operations.

Comanche Biopharma

Series B in 2024
Comanche Biopharma is a biopharmaceutical company focused on developing an investigational small interfering RNA (siRNA) medicine aimed at treating preterm preeclampsia. The company is committed to ensuring that all women and their babies have access to safe and effective therapies for life-threatening complications during pregnancy. Comanche Biopharma's mission emphasizes the importance of evidence-based and affordable solutions, enabling women to receive cost-effective treatments that address the root causes of preeclampsia.

Second Front

Venture Round in 2024
Second Front Systems, Inc. is a software development company based in Arlington, Virginia, that focuses on enhancing government access to venture capital-backed technologies for national security missions. Established in 2014, the company offers Atlas Fulcrum, a platform that helps users identify, assess, and utilize innovative commercial technologies. Additionally, Second Front provides program management and system integration services to facilitate the delivery of technology to military personnel. The High Technology Council, an enterprise consortium established by the company, brings together key industry players to leverage commercially developed technologies for government-funded national security efforts. Second Front also specializes in configuring, securing, and deploying compliant software applications for global government customers, ensuring that users have access to a fully managed production environment tailored for national security applications.

Perplexity

Series B in 2024
Perplexity is an artificial intelligence-based search engine platform that combines large language models with traditional search engines. It leverages natural language processing and generative AI technologies to deliver conversational responses to user queries, aiming to enhance the search experience beyond standard results. The platform is designed to facilitate the development of safe and beneficial artificial general intelligence, offering an open-source environment accessible to the public. This allows clients to acquire skills and knowledge in software development, positioning Perplexity as a bridge between conventional search capabilities and advanced AI-driven assistance.

VAST Data

Series E in 2023
VAST Data, Inc. specializes in developing innovative data storage solutions, offering a universal storage platform that integrates Intel’s Optane SSDs as a cache for data stored on quad-level cell (QLC) SSDs. Founded in 2016 and headquartered in New York, with an additional office in San Jose, VAST Data serves various industries, including animation, visual effects, deep learning, and enterprise backup recovery. The platform is designed to accelerate time-to-insight for workload-intensive applications, providing scalable performance, simple data management, and improved productivity for AI-driven organizations. Since its launch in 2019, VAST Data has gained recognition as a rapidly growing player in the data infrastructure sector.

Gravel

Venture Round in 2023
Developer of a construction workforce platform intended to optimize the workforce. The company's technology makes it simple to find qualified and trustworthy construction workers by democratizing access to blue-collar workforces without boundaries, it also provides residential repair & maintenance services and building materials online, enabling clients to solve quality labor shortages and deal with construction-related problems.

Second Front

Series B in 2023
Second Front Systems, Inc. is a software development company based in Arlington, Virginia, that focuses on enhancing government access to venture capital-backed technologies for national security missions. Established in 2014, the company offers Atlas Fulcrum, a platform that helps users identify, assess, and utilize innovative commercial technologies. Additionally, Second Front provides program management and system integration services to facilitate the delivery of technology to military personnel. The High Technology Council, an enterprise consortium established by the company, brings together key industry players to leverage commercially developed technologies for government-funded national security efforts. Second Front also specializes in configuring, securing, and deploying compliant software applications for global government customers, ensuring that users have access to a fully managed production environment tailored for national security applications.

Martian

Seed Round in 2023
Martian is a developer of an artificial intelligence platform focused on enhancing model performance through innovative AI solutions. The company aims to provide improved alignment in AI by creating more interpretable alternatives to the traditional transformer architecture. By automatically routing prompts to the most suitable language model, Martian ensures that clients can leverage advanced AI capabilities to optimize their products and services. This approach not only enhances product performance but also offers clients a more effective means of utilizing AI in their operations.

Ozone

Seed Round in 2023
Ozone is an innovative company that has developed an AI-powered video editing platform designed for seamless remote collaboration. As internet speeds continue to rise, Ozone capitalizes on this trend by offering a cloud-based solution that allows users to edit high-definition footage efficiently. The platform enables creative producers to create video mockups in seconds, perform color corrections with ease, and preview final results before exporting. By eliminating the need for bulky hardware and streamlining complex workflows, Ozone provides a lightweight and accessible editing experience that enhances creativity and productivity for content creators.

LXA

Seed Round in 2023
LXA is a fintech venture focused on reimagining Asia's mortgage ecosystem. Geared towards matching institutional capital pools and residential mortgage borrowers, this platform aims to utilize end-to-end technology to streamline the entire mortgage lifecycle, from loan origination and borrower processing to loan servicing. LXA was founded in early 2023 by seasoned executives across the asset management, insurance, mortgage, and technology industries to bridge the gap between mortgage assets and institutional capital in Asia, beginning with Singapore. Combining best practices from North American and European markets with a proprietary technology platform focused on digital credit decisioning and intelligent workflow orchestration, LXA provides the first of its kind solution to address strong demand from Asian insurers and borrowers for differentiated mortgage products.

Transfix

Series F in 2023
Transfix, Inc. is a trucking brokerage firm based in New York that specializes in connecting shippers with carriers for freight transportation across the United States. Founded in 2010, the company has developed an online freight management platform that utilizes advanced algorithms and business intelligence to enhance supply chain visibility and efficiency. Transfix offers services such as real-time shipment tracking, carrier performance insights, and support tailored to various industries, including retail, food, beverage, and manufacturing. By leveraging its Intelligent Freight Platform, Transfix aims to optimize logistics processes, reduce empty miles, and improve overall supply chain performance for its clients.

Waymark

Venture Round in 2023
Waymark is a company focused on enhancing access to and the quality of healthcare for individuals receiving Medicaid. It offers community-based healthcare services designed to improve health outcomes for Medicaid beneficiaries. The company collaborates with primary care providers and equips community care teams with essential resources, including health plans, insulin education, and training. Through these efforts, Waymark aims to support patients in effectively managing their health and navigating the healthcare system.

Mojo Vision

Series A in 2023
Mojo Vision Inc. is a company based in Saratoga, California, established in 2015, that specializes in augmented reality technology. The firm is focused on developing high-performance micro-LED displays for various applications, including consumer, enterprise, and government sectors. It has created the world's smallest and densest dynamic display integrated into a smart contact lens, designed to provide users with timely information without disrupting their focus. This innovative product allows for hands-free connectivity and access to relevant information, thereby minimizing reliance on traditional mobile devices. Additionally, Mojo Vision has formed a joint development agreement with Menicon Co., Ltd. to explore smart contact lens products further, leveraging its advanced micro-LED technology and manufacturing processes to disrupt the display industry.

Pair Eyewear

Series C in 2023
Pair Eyewear, founded in 2017 and based in New York, specializes in customizable eyeglasses for children. The company offers a unique product line that includes base frames, which are standard glasses, and top frames, which are snap-on fronts that can be easily changed to reflect a child's evolving interests and personalities. By leveraging an e-commerce platform, Pair Eyewear aims to transform the eyeglass experience into an engaging activity for children while simplifying the process for parents. The brand focuses on quality and affordability, providing eyewear that combines style with functionality, featuring hand-polished acetate frames and shatterproof polycarbonate lenses.

Pulumi

Series C in 2023
Pulumi Corporation operates an infrastructure-as-a-code platform that facilitates the development, deployment, and management of cloud applications and infrastructure. Founded in 2017 and based in Seattle, Washington, Pulumi offers the Pulumi SDK, an open-source tool that enables developers and DevOps teams to utilize programming languages for defining and managing cloud services across various environments, including public, private, and hybrid clouds. The platform supports a range of application types, from serverless functions to containerized applications, and emphasizes collaboration among teams to streamline cloud engineering processes. By providing a consistent workflow for delivering and securing applications, Pulumi helps businesses effectively create modern applications and manage their cloud environments.

Meeno

Seed Round in 2023
Meeno is a developer of an AI-driven relationship mentoring app designed for young adults, particularly targeting Gen Z. The platform offers personalized coaching exercises aimed at improving close relationships. By utilizing artificial intelligence, Meeno provides tailored feedback and guidance on various aspects of relationships, helping users to strengthen their social connections and enhance their overall well-being. The app is structured as a vertical AI product, focusing specifically on the unique needs and challenges faced by its audience.

Rocket.Chat

Series A in 2023
Rocket.Chat is an enterprise communication and collaboration platform that serves over 12 million users on more than 500,000 servers globally. It offers an open-source solution designed for team collaboration and omnichannel customer service, enabling users to exchange messages, organize video calls, and share files. The platform supports integration with various external communication tools, allowing companies to customize their communication environment while ensuring data ownership and compliance. Rocket.Chat provides a secure space for both internal and external communications, with features such as individual and group messaging, video conferencing, file uploading, screen sharing, and LiveChat. The company aims to replace traditional email with a real-time federated communications platform and plans to establish a marketplace to facilitate app development and business services built around its core offerings. An active community of over 1,000 developer-contributors continuously enhances the platform, ensuring it meets the evolving needs of its users.

Modyfi

Seed Round in 2023
Modyfi is an image editing platform that enhances creativity and collaboration in the photo-editing process. By utilizing artificial intelligence, it offers real-time, multi-user collaborative tools that include commenting, markups, and video chat functionalities. This allows designers and teams to work together seamlessly, centralizing projects and resources for efficient progress sharing and feedback collection. Modyfi aims to integrate image editing into clients' workflows, streamlining the overall design process.

Fizz

Series B in 2023
Fizz is an authorized platform designed to enhance community social structures, particularly within institutions. It develops online social media software that facilitates communication and the sharing of ideas, events, and experiences among users. The platform allows individuals to post secret confessions and ask questions within a closed community, promoting social interaction while maintaining anonymity. By leveraging these features, Fizz aims to foster a more connected and engaged community environment.

NeueHealth

Post in 2023
NeueHealth Inc is a healthcare company dedicated to providing high-quality, coordinated care to all health consumers, particularly those in aging and underserved populations. The company focuses on making healthcare accessible and affordable through strategic partnerships with providers and payors, aligning their interests to enhance the overall healthcare experience. By leveraging technology and data analytics, NeueHealth offers a suite of services that empower independent providers and medical groups to succeed in performance-based arrangements. This approach not only optimizes clinical outcomes but also aims to drive down costs and reduce systemic waste, ultimately delivering a more personalized and efficient healthcare experience for its members across various insurance markets, including the ACA Marketplace, Medicare, and Medicaid.

Functional Finance

Seed Round in 2023
Functional Finance is a fintech platform designed to enhance the operational efficiency of the insurance industry. It provides tools that facilitate various financial operations, including billing, invoicing, payment collection, statement generation, and real-time automatic reconciliation. By enabling insurance operators to unify and automate their financial workflows, the platform allows for seamless management of billing and financing processes without the need to overhaul existing infrastructure. This approach supports insurance companies in streamlining their financial activities and improving overall service delivery.

Nexo Therapeutics

Series A in 2023
Nexo Therapeutics is a biotechnology company focused on developing small-molecule therapies for cancer patients who have few effective treatment options. The company utilizes a specialized platform that integrates covalent ligand discovery with chemical biology to create innovative oncology drugs aimed at challenging targets that have been difficult to address in the past. By advancing its pipeline of novel therapies, Nexo Therapeutics seeks to provide new avenues for treatment, ultimately enhancing the care available to individuals battling cancer and other related diseases.

Gossamer Bio

Post in 2023
Gossamer Bio is a clinical-stage biopharmaceutical company based in San Diego that specializes in the discovery, development, and commercialization of innovative therapeutic products targeting significant unmet medical needs. Founded by former executives from Receptos, the company focuses on areas such as immunology, inflammation, fibrosis, and oncology. Its pipeline includes several promising candidates: Seralutinib, aimed at addressing pulmonary arterial hypertension; GB004, for inflammatory bowel disease; GB1275, targeting various oncology indications; and GB001, designed for moderate-to-severe eosinophilic asthma. Gossamer Bio's strategy involves leveraging a rich in-licensing environment to enhance its therapeutic offerings, supported by a team recognized for their successful track record in drug development.

Embrace

Venture Round in 2023
Embrace offers a unified observability and error monitoring platform tailored for mobile application development. This platform enables engineers to effectively manage the complexities associated with mobile environments, allowing them to proactively analyze user interactions and identify issues with detailed behavioral and technical context. Embrace's solution provides instant access to user sessions, facilitating a comprehensive understanding of events leading up to errors. By tracking every user activity—such as views, taps, and network requests—Embrace eliminates guesswork in troubleshooting, enhancing performance and enabling developers to create superior mobile experiences. The company's focus on delivering unique datasets empowers teams to prioritize and resolve issues swiftly, ultimately supporting the development of better mobile applications in an increasingly fragmented technological landscape.

SpyGlass Pharma

Series C in 2023
Spyglass Pharma specializes in developing innovative treatments for chronic ophthalmic diseases, leveraging advanced technology to enhance patient care and vision. The company focuses on creating ophthalmic devices and a drug delivery platform that addresses unmet needs in areas such as cataracts and lens replacement surgeries. Its delivery system is designed to be implanted alongside intraocular lenses during standard cataract procedures, allowing surgeons to administer multi-year therapies for chronic conditions. This approach aims to improve the accessibility and affordability of quality eye treatments for patients, ensuring better outcomes in ophthalmic care.

Tagworks Pharmaceuticals

Series A in 2023
Tagworks Pharmaceuticals is a privately held biotech company based in the Netherlands, established in 2011 as a spin-out from Philips Healthcare. The company focuses on developing innovative in vivo chemistry to enhance the effectiveness of cancer therapies and to facilitate novel companion diagnostics. Operating from the Radboud University Medical Center in Nijmegen, Tagworks specializes in antibody-based imaging and therapy technologies. Its proprietary approach allows for the selective chemical manipulation of tagged antibodies in vivo, which improves the efficacy of established methods like radioimmuno-imaging and antibody-drug conjugates. This technology enables medical professionals to conduct imaging with significantly reduced radiation exposure for patients.

Djust

Series A in 2023
DJUST is a provider of a cloud-based B2B platform that facilitates the rapid launch of e-commerce and e-procurement solutions for businesses. The company combines digital showrooms, an e-commerce marketplace, and customer relationship management (CRM) tools into a single integrated product. This streamlined approach allows clients to easily set up and expand their online operations, enhancing their ability to engage in digital commerce effectively. By offering a comprehensive solution, DJUST aims to simplify the process for businesses looking to establish or upgrade their online presence.

Granica

Series A in 2023
Granica provides a data readiness platform designed to support enterprises in effectively leveraging artificial intelligence. The platform enables data engineers and leaders to prepare AI-ready data that enhances the efficiency and safety of AI, machine learning, and analytics initiatives. By optimizing data sets for training and inference, Granica reduces storage costs by up to 60% and improves query performance by up to 56%. The company focuses on ensuring data privacy and mitigating the risks of sensitive data leakage while enhancing the accuracy and fairness of AI models. Granica curates and refines training data sets, selecting impactful samples to boost model performance and instill greater trust in AI applications. Targeting industries such as financial services, retail, geo-spatial intelligence, and autonomous vehicles, Granica aims to make AI implementations more effective and beneficial for its clients.

Instabase

Series C in 2023
Instabase, Inc. is a technology company based in San Francisco, California, founded in 2015. It specializes in developing a platform that automates document processing workflows and analyzes unstructured data. The platform integrates various capabilities, including optical character recognition, data classification and extraction, and natural language processing, allowing organizations across sectors such as insurance, finance, and healthcare to streamline operations and improve decision-making. Additionally, Instabase provides a developer kit that enables the creation of customized business applications, helping institutions embed artificial intelligence into their systems and processes. Through its innovative solutions, Instabase aims to address significant business challenges and facilitate transformational outcomes for its clients.

Strive Health

Series C in 2023
Strive Health, LLC, founded in 2018 and based in Denver, Colorado, specializes in solutions for chronic kidney disease. The company operates dialysis centers and employs a technology-enhanced clinical model to improve patient outcomes and experiences. Strive Health works collaboratively with innovative payers and providers to transform kidney care by focusing on the entire healthcare journey of chronic kidney disease patients, from primary care engagement to dialysis treatment. The company utilizes predictive analytics and comparative data to identify at-risk patients and aims to reinvent primary care to address kidney disease proactively, reducing the need for inpatient services and promoting home dialysis options. Backed by notable investors, Strive Health is committed to enhancing the management and care of patients with chronic kidney disease.

Sundeck

Seed Round in 2023
Sundeck is a data infrastructure and analytics company based in Santa Clara, California, founded by Jacques Nadeau in 2022. The company specializes in customizing the behavior of Snowflake queries to enhance their functionality. Sundeck's platform allows for warehouse optimization, adaptive routing, and granular cost control, empowering data engineers to address complex challenges in query management. By executing pre- and post-hook SQL across various business intelligence and AI tools, Sundeck enhances user creativity while providing robust control over data operations.

Union.ai

Series A in 2023
Union.ai is a Kubernetes-native workflow orchestration platform for data and machine learning at scale. Union.ai provides software users with the tools they need to move their ideas from concept to high-quality production. Union's aim is to organize the numerous processes required to train and grow the most sophisticated and dynamic machine learning and data products.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.